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A trial in the UK to study the effect on mortality from breast cancer of invitation for annual mammography from the age of 40–41,
has randomised a total of 160 921 women in the ratio 1 : 2 to the intervention and control arms. All breast cancers diagnosed in the
two arms have been identified, and the histology reviewed. This paper presents the results of an interim analysis using surrogate
outcome measures to compare predicted breast cancer mortality in the two arms based on 1287 cases diagnosed to 31.12.1999.
Due to earlier diagnosis, there is currently an 8% excess of invasive breast cancers in the intervention arm. The ratio of predicted
deaths at 10 years in the intervention arm relative to the control arm, adjusted for this excess diagnosis, ranges from 0.89 (95%
confidence interval (CI) 0.78–1.01) to 0.90 (95% CI 0.80–1.01). Screening from age 40 may result in a lower reduction in breast
cancer mortality than that observed in other trials including women below age 50. This analysis based on surrogate outcome
measures suggests that a reduction in breast cancer mortality may be observed in this trial. However, a number of assumptions have
been necessary and firm conclusions must await the analysis of observed mortality from breast cancer.
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At the time the NHS breast screening programme (NHSBSP) was
introduced in 1988, evidence from the randomised controlled trials
suggested that the benefit of screening was restricted to women
aged 50 and over, and it was decided to include women aged 50 –64
in the invitation system. The current Age Trial was established to
investigate the benefit of screening in younger women, specifically
the effectiveness of inviting women annually between the ages of
40 and 47–48.
The primary outcome measure of the trial is mortality from breast
cancer. However, detailed pathology information on all breast
cancer cases in the trial is also being collected, in order to permit an
earlier analysis of surrogate outcome measures to be performed.
MATERIALS AND METHODS
The methodology of the trial has been described in detail elsewhere
(Moss, 1999). Briefly, 160 921 women have been randomised in
the ratio 1 : 2 to an intervention arm and to a control arm.
Randomisation is individual, stratified by GP practice. Women in
the intervention arm are invited annually for screening by
mammography (by two views at first screen, and one view
thereafter unless otherwise indicated.) Women in the control arm
receive usual medical care. The original protocol to offer each
woman seven annual screens was subsequently extended to include
invitations up to the calendar year of each woman’s 48th birthday.
Ethics approval was obtained from London (formerly North
Thames) MREC.
Sample size
The trial was designed to randomise 195 000 women aged 40–41 at
entry, in order to have 80% power to detect a 20% reduction in
breast cancer mortality at 10 years of follow-up in the intervention
arm, at the 5% significance level, using a one-sided test. This was
based on an estimated mortality of 3.3 per 1000 in the control arm
in women free from breast cancer at entry into the trial (Moss,
1997). In 1999, recruitment was closed at 160 921 women due to
difficulties in recruiting new centres, the last women having been
randomised in 1997; the revised power is 73%.
Trial population
Recruitment of centres took place between 1991 and 1996 and
includes 23 NHSBSP breast screening units in England, Wales and
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Scotland. Figure 1 shows the number of women randomised by
trial arm; a total of 60 women have been excluded from analyses
for reasons given in the flowchart. As at March 2002, women in the
intervention arm had been offered a mean of 6.6 screens. Uptake of
invitation is around 70%, and 84% of women randomised to the
intervention arm were still invited at round 5. Details of uptake
and screening outcomes are given elsewhere (Moss et al, 2005).
All women are ‘flagged’ at the NHS central register, which
supplies information on all deaths and cancer registrations in the
trial population. In addition, information on breast cancer cases is
obtained from pathology laboratories and cancer registries and
cross matched against the trial population database. Breast cancer
cases included in this analysis are those diagnosed from trial entry
up to 31.12.1999, a period for which ascertainment of cancers was
estimated to be reasonably complete, based on age-specific
incidence rates for England and Wales.
Pathology data
For all trial cases identified, the original pathology report and
representative histology slides are requested from the relevant
laboratory. Each case is reviewed by a panel of three consultant
histopathologists, and a consensus diagnosis reached on tumour
size, nodal status, grade and histological type.
The review process has been described in detail elsewhere
(Anderson et al, 2002). The pathology variables have been
combined to calculate different prognostic indices. The Notting-
ham prognostic index (NPI) includes size, node status and grade
according to the formula (0.2 size (cm)þ grade (1–3)þ nodes
(1–3), where 1¼ node negative, 2¼ 1– 3 nodes positive and 3X3
nodes positive) (Blamey, 1996). The index has previously been
validated on series of clinical breast cancer cases using cutoff
points for four prognostic groups (Blamey, 1996; Todd et al, 1997).
Recently, the groupings have been reformulated for cases
diagnosed since 1987 (post use of adjuvant therapy) and five
prognostic groups identified; information on the 10-year survival
of each group and on the baseline hazard and hazard ratios for
individual components have been supplied by the Nottingham
group (Sarah Pinder, personal communication).
Two other prognostic indices have also been proposed. The
Swedish Two-County Studies Survival index uses information on
size, lymph node status, grade and histological type, and has been
developed using data from the randomised trial (Tabar et al,
1995b). The relative hazards of different factors, including lymph
node status, have previously been validated against observed
mortality reduction in the trial in different age-groups including
women aged 40–49 (Tabar et al, 1995a). Updated values for the
hazard ratios were obtained for this analysis (Duffy S, personal
communication). Assuming a 10-year baseline death rate of
0.04, the hazard was calculated for each cancer, and 10-year
survival estimates calculated for quantiles of this hazard in the
total data set.
The EDCAT index was developed using data from the Edinburgh
Randomised Trial of breast cancer screening, and includes size,
histological type, histological grade and node status/number
positive (Anderson et al, 2000). Size is included as six categories
as opposed to a continuous variable (1–9, 10– 14, 15–19, 20 –29,
30–49 and 50þmm). Histological type is classified as 1¼ special,
2¼ non-special. Grade and nodal status are categorised as for
the NPI. An index was formulated based on the hazard ratio
from a multivariate analysis including all four factors, and
survival associated with four groups (of equal numbers) cal-
culated. A simplified index formula is 0.7 size groupþ 1
 typeþ 1 gradeþ 1 node group. Information on the baseline
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Excluded from analysis 
•  Eight not traced at ONS/GRO 
•  10 deceased before entry   
•  Five emigrated before entry  
•  One male 
Excluded from analysis 
•  Eight not traced at ONS/GRO 
•  19 deceased before entry 
•  Five emigrated before entry 
•  Four males 
53 890 106 971
Figure 1 Flow diagram of the progress through the phases of the trial.
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hazard and hazard ratios for individual components have been
supplied by the investigators (Alexander F, personal communi-
cation).
For all the pathology variables in the present study, the
proportion unknown varies between the control and intervention
arm. However, for nearly all the invasive cases at least one of the
variables was known: 1124 using NPI and 1126 using the
Edinburgh index. For cases with missing data where at least one
variable was known, we predicted the prognostic index for the NPI
and Edinburgh index by fitting a regression model using those
cases where information was available on all factors. Where all
variables are unknown, the mean hazard of cases where at least one
factor is missing has been used. The Swedish Two Counties model
included a separate hazard ratio for cases where one or more
components were missing.
Statistics
Person-years were calculated from date of entry to date of death,
date of diagnosis of in situ or invasive cancer, or to 31.12.1999,
whichever was earliest.
For each of the prognostic indices, the predicted number of
cancers in each arm surviving at 10 years was calculated by
multiplying the 10-year survival rates by the numbers of cancers in
each prognostic group and summing over all groups. Cancers with
an unknown prognostic category were excluded from these
calculations.
To take account of the excess of cancers in the intervention arm
due to earlier diagnosis, the probability (p) of each screen-detected
cancer remaining asymptomatic to the end of the follow-up period
(31.12.1999 or date of death) was calculated using the formula
p(t4n)¼ eln where 1/l is the mean sojourn time (MST),
assuming the sojourn time to be exponentially distributed (Paci
et al, 2004). This probability was summed for the screen-detected
cancers in each prognostic category, and the total subtracted from
the observed number of cancers. A mean sojourn time of 1.0 years
for invasive cancers resulted in approximately equal incidence
rates in the trial arms; sensitivity analyses were conducted using
values of 0.75 and 1.25. When in situ cancers were included (for
the analysis using the Swedish Two Counties index), a mean
sojourn time of 1.75 years resulted in approximately equal rates;
the sensitivity analysis used values of 1.5 and 2.0.
To take account of the effect of lead-time due to advancing the
date of diagnosis by screening, the probability of death within 10
years of date of entry/randomisation has been calculated using the
hazard ratios for the individual components for each of the three
indices. These calculations used Cox proportional hazard models.
In the case of the NPI and the Edinburgh index, these were applied
to baseline hazard models. For the Swedish Two Counties model,
the 10-year baseline death rate of 0.04 was taken and assumed to
increase linearly with time. This yielded baseline survival estimates
for each year of follow-up. Adjustment for excess diagnosis was
made in this analysis by multiplying the probability of death for
each screen-detected cancer by the probability of that cancer
becoming symptomatic before the end of the follow-up period.
Variance for the relative risk was calculated using the formula
given by Day and Duffy (1996) for each prognostic index (adjusted
for the difference in the number of subjects in each arm).
RESULTS
Of the 1303 cases identified in the trial population up to
31.12.1999, 1217 have been reviewed by the pathology review
panel. For a further 31 the original pathology report was available,
while for 55 it has not been possible to trace the original pathology
report or hospital. A total of 16 cases included in analyses of breast
cancer incidence (Moss et al, 2005) have been excluded here
because the pathology review indicated that these were phyllodes
tumour (4), sarcoma (1) or malignant lymphoma (1), or down-
graded the lesion to ‘atypical hyperplasia’ (5) or benign (5). This
leaves 1287 cases for inclusion in the analysis.
Table 1 shows numbers of breast cancers in each arm of the trial
by invasive status and size category, by nodal status, grade and
histological type for invasive cancers only. A total of 68 cases (50 in
the control arm and 18 in the intervention arm) have been
classified as ‘advanced’ by one of the review panels on the basis of
information from the pathology report on clinical details (e.g.
treatment by chemotherapy of large tumour, cytology/core biopsy
only). These are included in the X50 mm category in Table 1. For
47 cases no information on size was available.
The percentage of cases in each of the categories in situ/
o10 mm, node negative and grade 1 is higher in the intervention
arm than in the control arm. All these differences are highly
significant (Po0.001). For all three factors there is a higher
percentage of cases with missing data in the control arm.
Rates per 1000 women-years are given in Table 2 for all cancers
and for invasive cancers only. Overall there is an excess of invasive
breast cancers in the intervention arm (RR¼ 1.08, 95% confidence
interval (CI) 0.95–1.21). Including in situ cancers, the excess is
17% (RR 1.17, 95% CI 1.05–1.32).
Rates of cases X20 mm are 12% lower in the intervention arm
than in the control arm (RR 0.88, 95% CI 0.74–1.05). Rates of
Table 1 Tumour size, node status and grade by trial arm
Frequency (%)
Intervention arm Control arm
Size (all cancers)
All CIS 69 (14.7) 54 (7.0)
1–9 mm 52 (11.1) 59 (7.6)
10–14 mm 81 (17.3) 124 (16.1)
15–19 mm 95 (20.3) 149 (19.3)
20–29 mm 98 (20.9) 209 (27.1)
30–49 mm 40 (8.5) 100 (13.0)
X50 mm 33 (7.1) 77 (10.0)
Unknown 10 37
Total 478 809
Node status (invasive cancers)
Negative 210 (54.5) 306 (45.7)
1–3 positive 87 (22.6) 181 (27.0)
X4 positive 37 (9.6) 95 (14.2)
Not sampled 51 (13.2) 88 (13.1)
Not known 24 85
Total 409 755
Grade (invasive cancers)
I 53 (13.6) 53 (7.6)
II 151 (38.8) 285 (40.9)
III 172 (44.2) 324 (46.5)
Not assessable 13 (3.3) 36 (5.2)
Unknown 20 57
Total 409 755
Histological type (invasive cancers)
Special 46 (11.9) 74 (10.5)
Part special 38 (9.8) 62 (8.8)
Not special 300 (77.7) 556 (79.1)
Rarea 2 (0.5) 11 (1.6)
Unknown 23 52
Total 409 755
Advanced, Post Chemotherapy, Core biopsy, Diagnosis at death and Cytology only
cancers were put in the 50+ mm category. Specimens larger than the slide were put
in the 30–49 mm category. aRare includes invasive micropapillary, metaplastic
carcinoma, atypical medullary and spindle cell tumour.
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node-positive cancers are 11% lower (RR 0.89, 95% CI 0.72– 1.10),
but rates of grade 3 tumours are 6% higher (RR 1.06, 95% CI 0.88,
1.27) in the intervention arm. However, none of these differences is
statistically significant.
Table 3 gives the numbers falling into the different categories
of the three prognostic indices, and the predicted numbers
surviving at 10 years from date of diagnosis, both for observed
cases, and with the intervention arm adjusted for excess diagnosis.
(The Swedish two Counties index includes in situ cases,
whereas the other two indices are restricted to invasive cancers).
Again, for each of the three indices there is a higher percentage of
cases in the intervention arm in the best prognostic groups, and
the proportion of cancers surviving at 10 years is higher in
the intervention arm than the control arm. The percentage
predicted to be surviving at 10 years in the intervention arm is
lower when the numbers are adjusted for excess diagnosis due to
the exclusion of a higher proportion of cases in the categories with
better prognosis.
Table 4 gives the predicted deaths within 10 years of date of
randomisation with the intervention arm adjusted for excess
diagnosis in the intervention arm, together with the risk ratios for
the intervention arm relative to the control arm.
Table 2 Rates of invasive and all breast cancers by study arm
Intervention arm (312 957 w. yearsa) Control arm (622 127 w.yearsa)
n Rate per 1000 w.years n Rate per 1000 w.years
All cancers 478 1.53 809 1.30
Invasive cancers 409 1.31 755 1.21
Invasive cancers X20 mm 171 0.55 386 0.62
Node positive 124 0.40 276 0.44
Grade III 172 0.55 324 0.52
aTo 31.12.1999, censored at date of death or diagnosis of breast cancer.
Table 3 NPI, Edinburgh and S2C categories and predicted 10-year survival from date of diagnosis by trial arm
Intervention arm Control arm


















0–2.4(excellent) 98 31 30.4 27.1 26.6 28 27.4
2.4–3.4 (good) 90 84 75.6 71.5 64.4 101 90.9
3.4–4.4 (moderate I) 83 118 97.9 107.2 89.0 211 175.1
4.4–5.4 (moderate II) 75 88 66 83.6 62.7 211 158.3
X5.4 (poor) 47 79 37.1 75.2 35.4 173 81.3
Not known 9 9 31
Total 409 307 (76.8) 373.7 278.1 (76.3) 755 533 (73.6)
Edinburgh index
0–6.1 96.6 71 68.6 59.8 57.8 77 74.4
6.1–7.5 90.91 96 87.3 84.8 77.0 153 139.1
7.5–8.8 80.21 83 66.6 76.9 61.6 164 131.5
X8.8 60.77 150 91.2 143.3 87.1 332 201.8
Not known 9 9 29
Total 409 313.7 (78.4) 373.7 283.5 (77.7) 755 546.8 (75.3)
S2C Group
0–3.30 93.7 149 139.6 112.0 104.9 138 129.3
3.30–6.00 83.9 85 71.3 67.5 56.6 143 120.0
6.00–12.47 74.2 142 105.4 125.1 92.8 292 216.7
X12.47 37.3 93 34.7 88.5 33.0 207 77.2
Not known 9 9 29
Total 478 351.0 (74.8) 402.2 287.3 (73.1) 809 543.2 (69.6)
aAssuming MST of 1.0 years for NPI, and EPI and MST of 1.75 for S2C.







N¼106 971 RR (95% CI)
Nottingham prognostic index 72.6 159.9 0.90 (0.80, 1.01)
Edinburgh prognostic index 76.8 170.8 0.89 (0.80, 1.00)
Swedish two Counties index 74.0 165.2 0.89 (0.78, 1.01)
aAdjusted for excess diagnosis, using MST of 1.0 for NPI and EPI, 1.75 for S2C.
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There is a reduction in predicted breast cancer mortality in the
intervention arm relative to the control arm of between 10 and 11%
depending on the prognostic index used; the estimated reductions
are of borderline statistical significance. The sensitivity analyses
give ranges for the relative risk (95% CIs) of 0.89(0.79– 1.00) –
0.91(0.81– 1.02) using the NPI, 0.88 (0.79–0.99) –0.90 (0.81–1.01)
using the Edinburgh index and 0.88 (0.77– 1.00)–0.90 (0.79–1.02)
using the Swedish Two Counties index.
DISCUSSION
The primary outcome measure of this trial is mortality from breast
cancer in the two arms. This analysis of surrogate outcome
measures predicts a reduction of 10– 11% in breast cancer
mortality in the intervention arm of the trial at 10 years from
randomisation. The results are consistent for the three prognostic
indices that have been used; however, there remains some
uncertainty around these predictions.
Estimates of mortality reduction from screening in women
under 50 have so far come primarily from subgroup analyses of
randomised controlled trials recruiting cohorts of women from
ages 40 or 45 upwards; meta-analyses of these trials have estimated
a reduction of 18% at an average of 12.7 years of follow-up in
women aged 40– 49 at entry (Hendrick et al, 1997), but there
remains debate as to how much of this effect is due to screening
occurring after age 50 (de Koning et al, 1995). The results of these
trials are summarised in Table 5, to allow comparison with the UK
trial.
There are a number of possible reasons why the effect of
screening on mortality in the current trial may be less than that
expected on the basis of other randomised trials. The present trial
is unique in inviting a cohort of women annually from age 40, and
none of the cancers in the present analysis was diagnosed over the
age of 50. Sensitivity of screening is likely to be lower at younger
ages, due to increased breast density; our estimate of sensitivity of
the first screening round is 74%, and 47–64% at later screens
(Moss et al, 2005); sensitivity in the Swedish Two County study in
women aged 40–49 has been estimated as 72–83% (Duffy et al,
1996) and in the Gothenburg trial as 84% (Bjurstam et al, 1997).
Uptake at first screen was 70% in our trial, compared to an uptake
of over 80% in the Swedish trials. These factors are likely to reduce
the impact of screening on mortality.
The attraction of evaluating screening trials using surrogate
end points lies in the ability to conduct earlier analyses, and
in more precise estimates of mortality reduction, although the
latter assumes no error in the survival probabilities. However,
there may be limitations to predicting mortality in this trial
using the NPI, as it was developed using a clinical series and
largely in older age groups. Nevertheless, the coefficients used here
for the NPI are those based on post-1987 cases (after
the introduction of adjuvant therapy), and this may explain the
greater similarity in outcome prediction between NPI and the
Edinburgh index observed here than when both were applied
to the Edinburgh randomised trial (Anderson et al, 2000). A
number of other potential problems with the use of surrogate
end points have been discussed by Morrison (1991), such
as variation of prognostic factors within measurement categories,
most of which would tend to lead to an underestimate of the
effect of screening. The analysis of the Swedish Two County Study
found that the predicted effect on mortality in the age group
40–49 years was conservative compared with that observed (Tabar
et al, 1995b). The authors hypothesised that this might be
attributable to an observed excess of cancers in the intervention
arm, possibly due to over diagnosis in this age group, or the
existence of a subgroup of women with a long sojourn time. Thus,
the mortality reductions predicted here may underestimate the
true reduction.
Ideally, predictions based on surrogate outcomes should
be based on equivalent numbers of cases in the two arms. In
the current analysis, there is an 8% excess of invasive breast
cancers in the intervention arm (17% if in situ cancers
are included). An excess is likely to remain until women in the
control arm are invited for screening as part of the national
programme at ages 50–52. The adjustment to predict mortality
at 10 years from the date of randomisation as opposed to
10 years from the date of diagnosis will take account of lead-time
bias due to the advancement in date of diagnosis of
screen-detected cancers. We have attempted to adjust for
excess diagnosis, and the effect of this adjustment does not
vary greatly with different assumptions concerning the mean
sojourn time. Analyses without this adjustment result in lower
estimates of mortality reduction ranging between 4 and 6% (data
not shown).
There is a 12% reduction in the rate of cancers X20 mm in the
intervention arm (equivalent to an 18% reduction adjusted for
excess diagnosis), and a 11% reduction in node-positive rate
(equivalent to a 17% reduction adjusted for excess diagnosis); both
these measures have been shown to have a direct relationship with
actual relative mortality reduction in randomised trials (Tabar et al,
1996).
In conclusion, results so far suggest that a reduction in breast
cancer mortality in the trial is likely to be observed; however, the
size of the reduction is uncertain and awaits definite results on
mortality. The first such analysis will be performed when data are
available on a mean follow-up of 10 years. Comparison of observed
and predicted mortality reductions in this trial (and in the
frequency trial (The Breast Screening Frequency Trial Group,
2002)) may provide further insight into the application of
surrogate outcome measures. When all women in the control
arm have been invited for their first screen at ages 50– 52, we
should be in a position to make a more accurate prediction of the
long-term effect on mortality.
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HIP study(20) 12 0.77 (0.53, 1.11) 18 67
Edinburgh(21)a 24 0.83 (0.54, 1.27) 14 61
Kopparberg(22) 24 0.76 (0.42, 1.40) 17 89
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aWomen aged 45–49 at entry. bWomen aged 43–49 at entry. cPreselection by
attendance for CBE.
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